🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT05815628
Recruiting Observational

Next-Generation-Sequencing Approach to Neutropenic Sepsis

NCT05815628 · tracked via the Priya Life Science Germany tracker
Sponsor
Boris Böll
Phase
Observational
Started
2024-06-05
Last updated
2025-08-08

Condition(s) studied

Febrile Neutropenia

Investigational drug(s) / intervention(s)

DISQVER

DISQVER: NGS based infection diagnosis

Study summary

The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for detecting bloodstream infection in neutropenic patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Informed consent * Neutropenia defined as \<500 ANC (Absolute neutrophil Count)/µl or \<1000 WBC (White bloddcell Count)/µl if ANC is not available * Fever (with an onset \< 24h) or Sepsis (with an onset \<24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection. Exclusion Criteria: * Age \< 18 years * Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available * Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time * Death is deemed imminent and inevitable

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
University Hospital of Cologne Cologne Germany Recruiting
Hospital Dessau Dessau Germany Recruiting
University Hospital of Essen Essen Germany Recruiting
University Hospital of Frankfurt Frankfurt am Main Germany Recruiting
University Hospital of Leipzig Leipzig Germany Recruiting
University Hospital of Magdeburg Magdeburg Germany Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05815628 on ClinicalTrials.gov ↗ ← All trials in Germany